• Consensus Rating: Hold
  • Consensus Price Target: $21.13
  • Forecasted Upside: 29.13%
  • Number of Analysts: 4
  • Breakdown:
  • 0 Sell Ratings
  • 4 Hold Ratings
  • 0 Buy Ratings
  • 0 Strong Buy Ratings
$16.36
▲ +0.09 (0.55%)

This chart shows the closing price for AFYA by one month, three months, or twelve months.

Skip Closing Price Chart
1 month | 3 months | 12 months
Get New Afya Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for AFYA and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for AFYA

Analyst Price Target is $21.13
▲ +29.13% Upside Potential
This price target is based on 4 analysts offering 12 month price targets for Afya in the last 3 months. The average price target is $21.13, with a high forecast of $23.00 and a low forecast of $19.00. The average price target represents a 29.13% upside from the last price of $16.36.

This chart shows the closing price for AFYA for the last year in relation to the current analyst high, average, and low pricetarget.

Read Analyst Price Chart DescriptionSkip Analyst Price Chart




Current Consensus is Hold

The current consensus among 4 investment analysts is to hold stock in Afya. This rating has held steady since December 2023, when it changed from a Moderate Buy consensus rating.

Past Monthly Recommendations

Move your mouse over past months for details

Read Past Recommendations DescriptionSkip Past Price Target Consensus Chart
  • 0 strong buy ratings
  • 2 buy ratings
  • 0 hold ratings
  • 0 sell ratings
5/30/2023
  • 0 strong buy ratings
  • 1 buy ratings
  • 0 hold ratings
  • 0 sell ratings
8/28/2023
  • 0 strong buy ratings
  • 1 buy ratings
  • 0 hold ratings
  • 0 sell ratings
11/26/2023
  • 0 strong buy ratings
  • 0 buy ratings
  • 3 hold ratings
  • 0 sell ratings
2/24/2024
  • 0 strong buy ratings
  • 0 buy ratings
  • 3 hold ratings
  • 0 sell ratings
5/24/2024
  • 0 strong buy ratings
  • 0 buy ratings
  • 3 hold ratings
  • 0 sell ratings
8/22/2024
  • 0 strong buy ratings
  • 0 buy ratings
  • 4 hold ratings
  • 0 sell ratings
10/21/2024
  • 0 strong buy ratings
  • 0 buy ratings
  • 4 hold ratings
  • 0 sell ratings
11/20/2024

Latest Recommendations

  • 0 strong buy ratings
  • 0 buy ratings
  • 4 hold ratings
  • 0 sell ratings

Display Ratings By
DateBrokerageActionRatingPrice TargetDetails
8/30/2024UBS GroupInitiated CoverageNeutral$19.50
6/21/2024Morgan StanleyLower TargetEqual Weight ➝ Equal Weight$21.00 ➝ $19.00
1/29/2024CitigroupInitiated CoverageNeutral$23.00
1/22/2024Morgan StanleyDowngradeOverweight ➝ Equal Weight$20.50 ➝ $23.00
11/27/2023JPMorgan Chase & Co.Reiterated RatingOverweight ➝ Neutral$22.00 ➝ $23.00
10/13/2023Morgan StanleyUpgradeEqual Weight ➝ Overweight$16.50 ➝ $20.50
11/22/2022Credit Suisse GroupLower TargetOutperform$19.00 ➝ $18.00
9/6/2022The Goldman Sachs GroupBoost Target$12.00 ➝ $13.50
8/24/2022The Goldman Sachs GroupReiterated RatingBuy ➝ Buy$12.00
4/8/2022Credit Suisse GroupUpgradeNeutral ➝ Outperform$18.00 ➝ $19.00
3/7/2022UBS GroupLower TargetBuy$27.00 ➝ $21.00
7/21/2021Morgan StanleyDowngradeOverweight ➝ Equal Weight$32.00 ➝ $28.50
4/15/2021UBS GroupUpgradeNeutral ➝ Buy
2/4/2021JPMorgan Chase & Co.UpgradeNeutral ➝ Overweight$34.00
10/19/2020JPMorgan Chase & Co.DowngradeOverweight ➝ Neutral$32.00
9/27/2020The Goldman Sachs GroupUpgradeNeutral ➝ Buy$23.90 ➝ $30.20
9/23/2020Credit Suisse GroupReiterated RatingHold$26.00
9/15/2020Bank of AmericaReiterated RatingBuy$32.00
8/19/2020Credit Suisse GroupInitiated CoverageNeutral$26.00
5/20/2020UBS GroupDowngradeBuy ➝ Neutral$31.00 ➝ $21.50
5/5/2020JPMorgan Chase & Co.Lower TargetOverweight$33.00 ➝ $24.50
3/20/2020Itau BBA SecuritiesUpgradeMarket Perform ➝ Outperform$28.00
3/9/2020JPMorgan Chase & Co.Lower TargetOverweight$35.00 ➝ $33.00
1/23/2020Bank of AmericaInitiated CoverageBuy$35.00
1/15/2020UBS GroupBoost TargetBuy$29.00 ➝ $31.00
(Data available from 11/21/2019 forward)

News Sentiment Rating

0.42 (Hold)

Our news sentiment rating is based on the average sentiment of articles about this company published in the media in the last 30 days of headlines and can range from 2 (very positive sentiment) to -2 (very negative sentiment).

News Sentiment Over Time

Move your mouse over past months for details

Skip to Current Sentiment Summary
  • 2 very positive mentions
  • 13 positive mentions
  • 5 negative mentions
  • 1 very negative mentions
4/24/2024
  • 5 very positive mentions
  • 10 positive mentions
  • 1 negative mentions
  • 1 very negative mentions
5/24/2024
  • 4 very positive mentions
  • 5 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
6/23/2024
  • 0 very positive mentions
  • 2 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
7/23/2024
  • 6 very positive mentions
  • 8 positive mentions
  • 4 negative mentions
  • 0 very negative mentions
8/22/2024
  • 2 very positive mentions
  • 9 positive mentions
  • 1 negative mentions
  • 1 very negative mentions
9/21/2024
  • 5 very positive mentions
  • 5 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
10/21/2024
  • 5 very positive mentions
  • 5 positive mentions
  • 3 negative mentions
  • 0 very negative mentions
11/20/2024

Current Sentiment

  • 5 very positive mentions
  • 5 positive mentions
  • 3 negative mentions
  • 0 very negative mentions
Afya logo
Afya Limited, through its subsidiaries, operates as a medical education group in Brazil. The company operates through three segments: Undergrad, Continuing Education, and Digital Services. It offers educational products and services, including medical schools, medical residency preparatory courses, graduate courses, and other programs to lifelong medical learners enrolled across its distribution network, as well as to third-party medical schools. The company also provides digital health services, such as subscription-based mobile app and website portal that focuses on assisting health professionals and students with clinical decision-making through tools, such as medical calculators, charts, and updated content, as well as prescriptions, clinical scores, medical procedures and laboratory exams, and others. It offers health sciences courses, which comprise medicine, dentistry, nursing, radiology, psychology, pharmacy, physical education, physiotherapy, nutrition, and biomedicine; and degree programs and courses in other subjects and disciplines, including undergraduate and post graduate courses in business administration, accounting, law, civil engineering, industrial engineering, and pedagogy. In addition, the company provides medical postgraduate specialization programs; printed and digital content; and an online medical education platform and practical medical training services. The company was founded in 1999 and is headquartered in Nova Lima, Brazil.
Read More

Today's Range

Now: $16.36
Low: $16.20
High: $16.43

50 Day Range

MA: $16.78
Low: $16.00
High: $18.09

52 Week Range

Now: $16.36
Low: $15.52
High: $22.48

Volume

67,933 shs

Average Volume

132,089 shs

Market Capitalization

$1.53 billion

P/E Ratio

13.19

Dividend Yield

N/A

Beta

0.91

Frequently Asked Questions

What sell-side analysts currently cover shares of Afya?

The following equities research analysts have issued stock ratings on Afya in the last year: Citigroup Inc., JPMorgan Chase & Co., Morgan Stanley, and UBS Group AG.
View the latest analyst ratings for AFYA.

What is the current price target for Afya?

0 Wall Street analysts have set twelve-month price targets for Afya in the last year. Their average twelve-month price target is $21.13, suggesting a possible upside of 29.1%. JPMorgan Chase & Co. has the highest price target set, predicting AFYA will reach $23.00 in the next twelve months. Morgan Stanley has the lowest price target set, forecasting a price of $19.00 for Afya in the next year.
View the latest price targets for AFYA.

What is the current consensus analyst rating for Afya?

Afya currently has 4 hold ratings from Wall Street analysts. The stock has a consensus analyst rating of "Hold." A "hold" rating indicates that analysts believe investors should keep any existing positions they have in AFYA, but not buy more shares or sell existing shares.
View the latest ratings for AFYA.

What other companies compete with Afya?

How do I contact Afya's investor relations team?

Afya's physical mailing address is ALAMEDA OSCAR NIEMEYER NO 119 SALA 504 VILA DA SERRA, NOVA LIMA D5, . The company's listed phone number is 553135157550 and its investor relations email address is [email protected]. The official website for Afya is www.afya.com.br. Learn More about contacing Afya investor relations.